Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430494 · ClinicalTrials.gov registry record
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
A clinical trial of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- 3,409
- Enrollment target
- 20
- Study locations
NCT01430494: Completed study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT01430494 is a study of Autosomal Dominant Polycystic Kidney Disease (ADPKD) that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 3,409 participants, above the 110-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (2999% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01430494, a study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- 3,409 participants
- Enrollment target
- 20
- Study locations
Study Summary
To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk for disease progression. The economic and quality life impact of ADPKD will be assessed. Subjects who terminated participation early from clinical trials with tolvaptan may also be followed.
Conditions Studied
Study Locations (20)
California
- Otsuka Investigational Site - Azusa
- Otsuka Investigational Site - Bakersfield
- Otsuka Investigational Site - Los Angeles
- Otsuka Investigational Site - Los Angeles
- Otsuka Investigational Site - Ontario
- Otsuka Investigational Site - San Diego
Florida
- Otsuka Investigational Site - Coral Gables
- Otsuka Investigational Site - Hudson
- Otsuka Investigational Site - Jacksonville
- Otsuka Investigational Site - Melbourne
- Otsuka Investigational Site - Port Charlotte
- Otsuka Investigational Site - Tampa
Arizona
- Otsuka Investigational Site 1 - Peoria
- Otsuka Investigational Site 2 - Peoria
- Otsuka Investigational Site - Tempe
Colorado
- Otsuka Investigational Site - Arvada
- Otsuka Investigational Site - Aurora
- Otsuka Investigational Site - Denver
Connecticut
- Otsuka Investigational Site - New Haven
District of Columbia
- Otsuka Investigational Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,409 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-10 |
What the finished NCT01430494 record still lists
NCT01430494 is an observational study that tracks outcomes without assigning an intervention. Its 3,409 participants enrollment target places it among the larger protocols in the corpus, above the 110-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (2999% higher).
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) appearing as the primary indexed condition, and to 0 interventions.
NCT01430494 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01430494 about?
NCT01430494 is a clinical study titled "Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease". To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population ...
What is the current status of trial NCT01430494?
This trial is currently completed. The enrollment target is 3,409 participants. The study started on 2011-06. Estimated completion is 2014-10.
What conditions does trial NCT01430494 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Who is sponsoring clinical trial NCT01430494?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01430494 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
RECRUITING · NA
-
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
RECRUITING · Phase 2
-
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
ACTIVE NOT RECRUITING
-
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia